Floatz logo

Pd-L1 T-Hank

Advanced Triple Negative Breast Cancer

ImmunityBio, Inc.Cell therapyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

447 Active assets in the Advanced Triple Negative Breast Cancer cohort.

Asset / SponsorPhaseRating
Capivasertib
AstraZeneca
Phase 3BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 4BB
Carboplatin
M.D. Anderson Cancer Center
Phase 4BB
Veliparib
National Cancer Institute (NCI)
Phase 3BB
Atezolizumab
European Institute of Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

Pd-L1 T-Hank is also rated in:

cutaneous neuroendocrine carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
Microsatellite InstabilityDormant
CCC
Indicative ·
53 / 100
View asset →
Mismatch Repair DeficiencyDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →